Catalent, Inc. (NYSE:CTLT) Shares Acquired by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Catalent, Inc. (NYSE:CTLT) by 2.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,907 shares of the company’s stock after buying an additional 434 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Catalent were worth $849,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. abrdn plc lifted its holdings in shares of Catalent by 338.2% in the 4th quarter. abrdn plc now owns 192,443 shares of the company’s stock valued at $8,646,000 after buying an additional 148,522 shares during the period. Federated Hermes Inc. acquired a new position in shares of Catalent in the 4th quarter valued at about $46,000. Daiwa Securities Group Inc. lifted its holdings in shares of Catalent by 2.2% in the 4th quarter. Daiwa Securities Group Inc. now owns 24,380 shares of the company’s stock valued at $1,096,000 after buying an additional 535 shares during the period. Rakuten Securities Inc. acquired a new position in shares of Catalent in the 4th quarter valued at about $46,000. Finally, Vontobel Holding Ltd. acquired a new position in shares of Catalent in the 4th quarter valued at about $352,000.

Catalent Price Performance

NYSE:CTLT opened at $55.81 on Friday. Catalent, Inc. has a 12 month low of $31.45 and a 12 month high of $60.20. The stock has a 50 day moving average of $56.76 and a two-hundred day moving average of $48.53. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The firm has a market cap of $10.10 billion, a P/E ratio of -8.21, a price-to-earnings-growth ratio of 6.04 and a beta of 1.20.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter last year, the company earned $0.62 earnings per share. On average, analysts expect that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CTLT shares. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. Stephens restated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. StockNews.com started coverage on Catalent in a research note on Friday, April 19th. They issued a “sell” rating for the company. Barclays lifted their price target on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Finally, UBS Group restated a “neutral” rating and issued a $63.50 price target (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.